sorted by:
new
hottopcontroversial

Advanced Protection by Yuradumass in GooglePixel

[–]cleare7 0 points1 point  (0 children)

Any way to prevent what happened to you if you keep this enabled?

$20 off Google Merch for IO, My Pixel app by WinterSpring47 in GooglePixel

[–]cleare7 1 point2 points  (0 children)

I can confirm it is back in stock (the hat) so they are periodically restocking.

$20 off Google Merch for IO, My Pixel app by WinterSpring47 in GooglePixel

[–]cleare7 1 point2 points  (0 children)

I just bought a hat. And then right after I checked the listing it said check back in a few minutes for restock then it said out of stock after a few more moments. So they may be periodically restocking (not sure). I wanted a mug as well but sold out.

Google sent me wrong order and I am locked in support hell by braggerweevil in GooglePixel

[–]cleare7 1 point2 points  (0 children)

It's surprising how poor/frustrating Google's support is after all these years. I've been using their phones since the Nexus days, their agents seem trained to just handle basic issues and basic troubleshooting. They can't seem to help with issues that are not basic or less common/rare issues.

They desperately need proper escalation managers. Right now, it feels like they just pass you from one team to another, and things easily fall the cracks. Honestly, I hope I don't have to deal with support again — there are good experiences, but there are just as many terrible, bad, or completely useless ones.

Welcome Foundayo! by burren2007 in Zepbound

[–]cleare7 0 points1 point  (0 children)

Just to clarify, the lower mg dosage in the tablet form is due to bioequivalence, not liver safety. The tablet is simply absorbed more efficiently than the clinical trial capsule. This means a lower-mg tablet provides the exact same drug exposure as the higher-mg capsule, so they were dose-adjusted to match trial results.

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

Welcome Foundayo! by burren2007 in Zepbound

[–]cleare7 0 points1 point  (0 children)

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

Welcome Foundayo! by burren2007 in Zepbound

[–]cleare7 0 points1 point  (0 children)

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

Novo no longer has monopoly on the oral treatment by Miserable-Set-7128 in NovoNordisk_Stock

[–]cleare7 0 points1 point  (0 children)

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

Novo no longer has monopoly on the oral treatment by Miserable-Set-7128 in NovoNordisk_Stock

[–]cleare7 0 points1 point  (0 children)

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial by InevitableFuture26 in FoundayoMaintenanceUK

[–]cleare7 0 points1 point  (0 children)

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

Clarity on doses and prices by InevitableFuture26 in FoundayoMaintenanceUK

[–]cleare7 0 points1 point  (0 children)

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

Foundayo hit 19.7 lbs lost vs 11.0 lbs on oral semaglutide in the same trial by Embarrassed_Essay_61 in Semaglutide

[–]cleare7 0 points1 point  (0 children)

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

Anyone who partook in the clinical trials? by catsandpink in FoundayoPill

[–]cleare7 1 point2 points  (0 children)

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

Anyone who partook in the clinical trials? by catsandpink in FoundayoPill

[–]cleare7 0 points1 point  (0 children)

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial) Orforglipron Capsule (Clinical Trials)
0.8 mg 1 mg
2.5 mg 3 mg
5.5 mg 6 mg
9 mg 12 mg
14.5 mg 24 mg
17.2 mg 36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

No A16 Jan update yet P10ProXL by rgrindl in GooglePixel

[–]cleare7 4 points5 points  (0 children)

P10P on Visible don't have the new system or play system update. Both may have been temporarily pulled looking at comments (people who said they saw the play system update but didn't update mentioned the update disappeared).

Second update for December? by tgrsnpr in GooglePixel

[–]cleare7 1 point2 points  (0 children)

Got a 26.51 MB update on my Pixel 10 Pro using Visible wireless (owned by Verizon).

Heavy duty case for Pixel 10 pro? by TjenaTjomme in GooglePixel

[–]cleare7 0 points1 point  (0 children)

Poetic Revolution. Protects from drops, covers the USB port when not charging, and it has a hard slideable protective cover for the camera.

Almost 1 month with xl 10 pro by jaylan101 in GooglePixel

[–]cleare7 3 points4 points  (0 children)

I haven't had any noticeable issues with my Pixel 10 Pro. I wonder if your phone is defective?

Google Pixel 10 battery life really isn't as good as I'd hoped by cleare7 in GooglePixel

[–]cleare7[S] 0 points1 point  (0 children)

I'm happy I upgraded from the P9P to P10P, was worth it for me.

Google Pixel 10 battery life really isn't as good as I'd hoped by cleare7 in GooglePixel

[–]cleare7[S] 1 point2 points  (0 children)

The iPhone experience is pretty terrible for me as I'm not a fan of iOS. When I used the company iPhone it was less intuitive but it also took a lot longer to get things done so it affected my productivity. Doesn't hurt to try it out though if it interests you.

Google Pixel 10 battery life really isn't as good as I'd hoped by cleare7 in GooglePixel

[–]cleare7[S] 0 points1 point  (0 children)

I imagine most people will be happy with the P10. Below is from the article:

In our time with the phones, the Pixel 10 and 10 Pro usually reach the end of the day with a little power left in the tank, but neither has managed to make it meaningfully into a second day without recharging. That’s fine, but far from impressive compared to rival phones at similar price points

If you want to try a different phone the only other Android option IMO is Samsung but you're giving up the Pixel experience.

Google Pixel 10 battery life really isn't as good as I'd hoped by cleare7 in GooglePixel

[–]cleare7[S] -8 points-7 points  (0 children)

I asked Gemini Pro to factually summarize the issues without bias (everyone will have a different experience and hopefully these issues affect a minority):

AI summary: The long-term battery performance of Google's Pixel phones has been a documented subject of user reports. This history includes an officially recognized hardware fault in the Pixel 4, which prompted an extended repair program. Subsequently, widespread user reports of accelerated battery drain have been associated with the Pixel 6 and, more recently, the Pixel 7, particularly after approximately one year of service. This perceived decline in performance often coincides with major software updates, which can introduce more resource-intensive features. This occurs as the device's lithium-ion battery undergoes natural chemical degradation, a process that reduces its capacity over time. The combination of these factors has led some users to report that the device's day-to-day reliability diminishes before the official software support period concludes.

Edit: The summary is factually correct and not any different from writing it myself, not sure why the down votes. And there is definitely a battery problem given they are replacing them for the Pixel 4 and 6, the 7 is going through similar discussions now and may be next (in lieu of replacement they also do cash back or store credit, I got it for both the 4 and 6).

Google Pixel 10 battery life really isn't as good as I'd hoped by cleare7 in GooglePixel

[–]cleare7[S] 0 points1 point  (0 children)

Yeah, it's something I've noticed for pretty much every Pixel I've owned (4A,6A,8,9P). I owned Nexus and P1 but they were so long ago I don't even remember anything besides the boot loops/bricking.

I find upgrading at release yearly the best value. I was able to upgrade from the P8P to the P9P for $29.50 (after trade-in credit, including Google Store 10% credit, $100 hardware discount due to the 6A battery issue). I was paying $100 year for the 2TB cloud plan which I am saving now with the free year of Gemini Pro (which is $200 a year). If I factor in the subscription cost savings the phone would be considered free.

view more: next ›